Invion (AU:IVX) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Invion Limited has initiated its Phase I/II trial for a new non-melanoma skin cancer treatment using their innovative drug INV043, which promises effective results with minimal side effects compared to traditional methods. The trial, conducted in Queensland, aims to offer an alternative to surgery, which often results in scarring and pain. This development is part of Invion’s broader strategy to leverage positive findings from previous cancer trials to expand into other cancer treatments.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.